EyePoint director Karen L. Zaderej buys $52,258 in stock By Investing.com

Karen L. Zaderej, a director at EyePoint, Inc. (), purchased 10,600 shares of the company’s common stock for a total value of $52,258. The transaction took place on August 18, 2026.

The shares were acquired at a price of $4.93 per share. Following this purchase, Ms. Zaderej directly holds 49,100 shares of EyePoint common stock.The insider purchase comes as the stock currently trades at $5.47, up from her purchase price, though shares remain down 62.68% over the past week. According to InvestingPro analysis, which indicates the stock is overvalued relative to its Fair Value, one InvestingPro Tip notes that the RSI suggests the stock is in oversold territory. Investors seeking deeper insights can access 17 additional ProTips and a comprehensive Pro Research Report on EYPT, part of InvestingPro’s coverage of over 1,400 US equities.

In other recent news, EyePoint Inc. has faced a series of analyst downgrades following mixed results from its LUGANO Phase III trial for the drug Duravyu. Chardan downgraded the company to Neutral from Buy, citing increased regulatory uncertainty surrounding the LUCIA trial and reducing the drug’s approval probability to 10% from 60%. RBC Capital also downgraded EyePoint to Sector Perform from Outperform after the LUGANO trial failed to meet its primary non-inferiority endpoint, viewing the trial data as negative. Meanwhile, Jefferies maintained its Buy rating but lowered the price target to $8.00 from $30.00, attributing the trial miss to vision loss in a subset of patients unrelated to wet AMD.

Despite these setbacks, Guggenheim and Stifel reiterated their Buy ratings, with Guggenheim setting a price target of $68.00 and Stifel at $40.00. Both firms acknowledged the trial’s failure to meet its primary endpoint but highlighted the specific patient imbalances affecting the results. The LUGANO trial’s primary endpoint miss was partly due to nine patients experiencing significant vision loss from conditions unrelated to wet AMD. These developments underscore the challenges EyePoint faces with its current clinical trials.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.